SNC-103

N/A

Report date: 2024/02/19 16:44:14

Base Information

Drug NameSNC-103
Drug Alias Name靶向CD19的嵌合抗原受体基因修饰的NK细胞注射液Anti-CD19 CAR-Engineered NK cells therapy (Shanghai Simnova Biotechnology)SNC-103SNC103F01 +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Simnova Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Simnova Biotechnology Co Ltd
Inactive CompaniesBeijing Gao Boren Hospital Co Ltd
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous +[7] 
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A